말초 T세포 림프종(PTCL) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Peripheral T-Cell Lymphoma (PTCL) Market Outlook

Thelansis's "Peripheral T-Cell Lymphoma (PTCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Peripheral T-Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Peripheral T-Cell Lymphoma (PTCL) Overview

Peripheral T-cell lymphoma (PTCL) represents a rare, heterogeneous, and highly aggressive group of mature T-cell and natural killer (NK)-cell neoplasms, accounting for approximately 10-15% of all non-Hodgkin lymphomas. The disease comprises multiple biologically distinct subtypes, most commonly PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL), each driven by epigenetic alterations, aberrant T-cell receptor signaling, and oncogenic mutations.

Clinically, PTCL is characterized by rapid disease progression, presenting with generalized lymphadenopathy, systemic B symptoms (fever, night sweats, weight loss), and frequent extranodal involvement, including the skin, bone marrow, and liver. The disease course is typically aggressive, with poor prognosis compared to B-cell lymphomas.

Historically, frontline treatment with CHOP-based chemotherapy resulted in suboptimal outcomes and high relapse rates due to intrinsic chemoresistance. The treatment paradigm has since evolved, particularly with the incorporation of targeted therapies. For CD30-positive subtypes (notably ALCL), the combination of brentuximab vedotin with chemotherapy (BV-CHP) has become a preferred frontline regimen.

Consolidation with autologous stem cell transplantation (ASCT) is commonly pursued in eligible patients achieving remission. In the relapsed/refractory setting, treatment relies on novel targeted agents, including histone deacetylase (HDAC) inhibitors and antifolate therapies such as pralatrexate. Despite these advances, outcomes remain limited, underscoring a significant unmet need for more effective and durable therapies.

Key Highlights

• In France, diagnosed incident PTCL cases are projected to increase from 1,448 to 1,981, indicating a rising disease burden.
• PTCL remains a rare but highly aggressive lymphoma subtype with poor prognosis compared to B-cell lymphomas.
• High relapse rates persist due to intrinsic resistance to conventional chemotherapy.
• Treatment paradigm is shifting toward targeted therapies (e.g., brentuximab vedotin) and precision medicine approaches.
• Significant unmet need exists in relapsed/refractory PTCL and long-term disease control.

Market Overview

• The France PTCL market is projected to grow from $21M to $32M, reflecting moderate market expansion.
• Market growth is driven by:
• Adoption of targeted therapies and antibody-drug conjugates
• Increasing use of transplant and second-line treatment strategies
• Despite low patient numbers, market value is supported by high-cost therapies and intensive treatment approaches.
• Continued innovation in epigenetic therapies and novel immuno-oncology agents is expected to shape future market dynamics.
• Future growth will depend on effective therapies for relapsed/refractory patients and improved survival outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Xenothera SAS
• Dizal Pharmaceuticals
• Chipscreen Biosciences, Ltd.
• Boryung Pharmaceutical Co., Ltd
• SecuraBio
• Acrotech Biopharma Inc.
• Boston Immune Technologies and Therapeutics
• Corvus Pharmaceuticals, Inc.
• SciTech Development, Inc.
• Aileron Therapeutics, Inc.
• AstraZeneca
• Kymera Therapeutics, Inc.
• Bio-Path Holdings, Inc.
• Pfizer

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)